NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

Thanks, Hygro, for clarifying that point for me.
However, I think that arguments over the design of the study will soon be redundant in the light of the number of long term survivors (ie cures) that have been produced by the addition of DCVax to the S.O.C. This number could very well be dwarfed by the percentage of survivors in Prof Liau's current study (DCVax + Pemrolizumab + poly-ICLC) in which median survival has not not yet been reached with over 50% surviving longer than 2 years.
Now if you tell me that this trial will not play a part in the Regulators decision on the DCVax-L trial I will disagree with you. Regulators are not fools (some may be venal and veer towards Big Pharma) but they are highly unlikely to turn down a treatment which most people accept as having been shown to work (not you, quite clearly) for a condition which otherwise is a death sentence.
If a Regulator truly is undecided I am sure that it would easily find a way to give provisional acceptance now and then review it after several years of observation in clinical pratice.